FDA’s ‘Monster’ Proposed Rule Targets Patent Use Codes, Paragraph IV Certification
This article was originally published in The Pink Sheet Daily
Executive Summary
Industry has 90 days to comment on FDA’s current handling of generic challenges to brand protections.